61 related articles for article (PubMed ID: 38660631)
1. Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial.
Gao X; Ji K; Jia Y; Shan F; Chen Y; Xu N; Jia Z; Liu T; Yang N; Zhong H; Li C; Guo Z; Fan Q; Lin X; Zhang Y; Ren H; Yang H; Yao Z; Liu W; Wang ZM; Li B; Xia M; Shen L; Li Z; Ji J
Nat Med; 2024 May; ():. PubMed ID: 38778212
[TBL] [Abstract][Full Text] [Related]
2. First‑line programmed cell death 1 inhibitor plus chemotherapy vs. standard treatment in patients with recurrent or metastatic oral squamous cell carcinoma: A retrospective cohort study.
Cheng L; Chai C; Liu Y; Jiao J
Oncol Lett; 2024 Aug; 28(2):352. PubMed ID: 38872864
[TBL] [Abstract][Full Text] [Related]
3. Human epidermal growth factor receptor 2 expression level and combined positive score can evaluate efficacy of advanced gastric cancer.
Ma XT; Ou K; Yang WW; Cao BY; Yang L
World J Clin Oncol; 2024 May; 15(5):635-643. PubMed ID: 38835847
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with the efficacy of first-line nivolumab plus chemotherapy in advanced gastric cancer patients with deficient mismatch repair.
Park YG; Kim HD; Hyung J; Park YS; Ryu MH
Gastric Cancer; 2024 May; ():. PubMed ID: 38780852
[TBL] [Abstract][Full Text] [Related]
5. Interpretation of PD-L1 expression in gastric cancer: summary of a consensus meeting of Korean gastrointestinal pathologists.
Ahn S; Kwak Y; Kwon GY; Kim KM; Kim M; Kim H; Park YS; Oh HJ; Lee K; Lee SH; Lee HS
J Pathol Transl Med; 2024 May; 58(3):103-116. PubMed ID: 38653580
[TBL] [Abstract][Full Text] [Related]
6. Impact of CYP2A6 Gene Polymorphism on the Efficacy and Safety of S-1 Therapy in Patients with Gastric Cancer: A Systematic Review and Meta-Analysis.
Dong T; Gu Y
Chemotherapy; 2024 Apr; ():1-10. PubMed ID: 38599185
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors
Liu S; Dou L; Li S
Therap Adv Gastroenterol; 2024; 17():17562848241233134. PubMed ID: 38425370
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Programmed Death-1/Programmed Death-Ligand 1 Inhibitor for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
Liao PF; Wang PY; Peng TR
Curr Oncol; 2023 Nov; 30(11):9940-9952. PubMed ID: 37999142
[No Abstract] [Full Text] [Related]
9. Effectiveness and tolerability of programmed cell death protein-1 inhibitor + chemotherapy compared to chemotherapy for upper gastrointestinal tract cancers.
Zhang XM; Yang T; Xu YY; Li BZ; Shen W; Hu WQ; Yan CW; Zong L
World J Gastrointest Oncol; 2024 Apr; 16(4):1613-1625. PubMed ID: 38660631
[TBL] [Abstract][Full Text] [Related]
10. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Janjigian YY; Shitara K; Moehler M; Garrido M; Salman P; Shen L; Wyrwicz L; Yamaguchi K; Skoczylas T; Campos Bragagnoli A; Liu T; Schenker M; Yanez P; Tehfe M; Kowalyszyn R; Karamouzis MV; Bruges R; Zander T; Pazo-Cid R; Hitre E; Feeney K; Cleary JM; Poulart V; Cullen D; Lei M; Xiao H; Kondo K; Li M; Ajani JA
Lancet; 2021 Jul; 398(10294):27-40. PubMed ID: 34102137
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of PD-1/PD-L1 inhibitor combined with chemotherapy versus chemotherapy alone in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis.
Liu BW; Shang QX; Yang YS; Chen LQ
Front Oncol; 2023; 13():1077675. PubMed ID: 37114136
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of first‑line anti‑PD‑1/PD‑L1 immunotherapy for gastric esophageal cancer: A systematic review and meta‑analysis of phase III randomized controlled trials.
Duan X; Du H; Qi R; Yuan M; Shi J
Exp Ther Med; 2023 May; 25(5):216. PubMed ID: 37123204
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of PD-1 Inhibitors in First-Line Treatment for Advanced Gastroesophageal Junction and Gastric Cancer by Subgroups: A Systematic Review and Meta-Analysis.
Fei S; Lu Y; Chen J; Qi J; Wu W; Wang B; Han Y; Wang K; Han X; Zhou H; Wang J; Chen J
Chemotherapy; 2023; 68(4):197-209. PubMed ID: 37331333
[TBL] [Abstract][Full Text] [Related]
14. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
15. Sintilimab combined neoadjuvant intraperitoneal and systemic chemotherapy in gastric cancer with peritoneal metastasis.
Yuan H; Lu S; Shi M; Yang Z; Liu W; Ni Z; Yao X; Hua Z; Feng R; Zheng Y; Wang Z; Sah BK; Chen M; Zhu Z; He C; Li C; Zhang J; Yan C; Yan M; Zhu Z
Future Oncol; 2023 Dec; 19(38):2517-2523. PubMed ID: 37212686
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]